PI4KA — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL188830	0.75	13/20
SCHEMBL8273	0.54	10/20
SCHEMBL9120	0.54	10/20
SCHEMBL258584	0.54	10/20
SCHEMBL106573	0.59	9/20
SCHEMBL42335	0.57	8/20
SCHEMBL42314	0.56	8/20
SCHEMBL8566	0.53	8/20
SCHEMBL24640	0.50	8/20
SCHEMBL184566	0.55	7/20
SCHEMBL134910	0.54	6/20
SCHEMBL113955	0.50	6/20
SCHEMBL48258	0.41	6/20
SCHEMBL179434	1.00	5/20
SCHEMBL179409	0.71	5/20
SCHEMBL179437	0.71	5/20
SCHEMBL179458	0.71	5/20
SCHEMBL179551	0.54	5/20
SCHEMBL184788	0.53	5/20
SCHEMBL184747	0.50	5/20

Clinical trials — most relevant to PI4KA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)	PHASE2	COMPLETED
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor	PHASE2	COMPLETED
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer	PHASE2	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)	PHASE1	ACTIVE_NOT_RECRUITING
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Compassionate Use of BYL 719 Alpelisib	nan	NO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a PI4KA binder may also engage these)

Protein	Name	Similarity
O08662	—	1.000	O08662 →
E9Q3L2	—	1.000	E9Q3L2 →
O02811	—	1.000	O02811 →
Q9SXA1	—	1.000	Q9SXA1 →
Q8BKX6	—	1.000	Q8BKX6 →
SMG1	Serine/threonine-protein kinase SMG1	0.999	landscape →
Q9DEI1	—	0.998	Q9DEI1 →
Q5MNV8	—	0.998	Q5MNV8 →
P42173	—	0.998	P42173 →
P97313	—	0.998	P97313 →
F4I893	—	0.997	F4I893 →
O14715	—	0.997	O14715 →
ATR	Serine/threonine-protein kinase ATR	0.996	landscape →
Q9DE14	—	0.996	Q9DE14 →
Q6CAD2	—	0.996	Q6CAD2 →
A1Z8X3	—	0.996	A1Z8X3 →
Q9JKK8	—	0.996	Q9JKK8 →
Q9SWA6	—	0.996	Q9SWA6 →
Q18892	—	0.996	Q18892 →
Q80UK8	—	0.996	Q80UK8 →
Q96N11	—	0.996	Q96N11 →
Q99666	—	0.995	Q99666 →
Q7Z3J3	—	0.995	Q7Z3J3 →
C5J7W8	—	0.995	C5J7W8 →
Q8WN22	—	0.994	Q8WN22 →
F4IGA5	—	0.994	F4IGA5 →
P32333	—	0.994	P32333 →
Q70PP2	—	0.994	Q70PP2 →
O74447	—	0.994	O74447 →
E1C231	—	0.994	E1C231 →